IL-23 inhibitors for moderate-to-severe psoriasis.

Q1 Medicine
Erin Ibler, Kenneth B Gordon
{"title":"IL-23 inhibitors for moderate-to-severe psoriasis.","authors":"Erin Ibler,&nbsp;Kenneth B Gordon","doi":"10.12788/j.sder.2018.047","DOIUrl":null,"url":null,"abstract":"<p><p>Since the identification of high levels of interleukin 23 (IL- 23) in psoriasis lesional skin, as well as finding that IL-23 was the most important source of the p40 subunit shared by IL-12 and IL-23, significant effort has been made in identifying potential new drugs that specifically block the unique IL-23 p19 subunit. At this time, 2 inhibitors of IL-23 p19 have been approved by the United States Food and Drug Administration, guselkumab and tildrakizumab. Two other agents, risankizumab and mirikizumab, have completed phase 3 and phase 2 of development, respectively. Pivotal trials in the development of these agents and clinical use of the approved agents are discussed. Thus far, this class of medications seems to provide a high level of efficacy, along with infrequent dosing and very favorable safety results.</p>","PeriodicalId":21714,"journal":{"name":"Seminars in cutaneous medicine and surgery","volume":"37 3","pages":"158-162"},"PeriodicalIF":0.0000,"publicationDate":"2018-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"14","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminars in cutaneous medicine and surgery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.12788/j.sder.2018.047","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 14

Abstract

Since the identification of high levels of interleukin 23 (IL- 23) in psoriasis lesional skin, as well as finding that IL-23 was the most important source of the p40 subunit shared by IL-12 and IL-23, significant effort has been made in identifying potential new drugs that specifically block the unique IL-23 p19 subunit. At this time, 2 inhibitors of IL-23 p19 have been approved by the United States Food and Drug Administration, guselkumab and tildrakizumab. Two other agents, risankizumab and mirikizumab, have completed phase 3 and phase 2 of development, respectively. Pivotal trials in the development of these agents and clinical use of the approved agents are discussed. Thus far, this class of medications seems to provide a high level of efficacy, along with infrequent dosing and very favorable safety results.

IL-23抑制剂治疗中重度牛皮癣。
由于在银屑病皮损皮肤中发现了高水平的白细胞介素23 (IL- 23),以及发现IL-23是IL-12和IL-23共有的p40亚基的最重要来源,因此在寻找特异性阻断IL-23独特的p19亚基的潜在新药方面已经做出了重大努力。目前,两种il - 23p19抑制剂已被美国食品和药物管理局批准,guselkumab和tildrakizumab。另外两种药物,risankizumab和mirikizumab,分别完成了3期和2期的开发。讨论了这些药物开发的关键试验和批准的药物的临床应用。到目前为止,这类药物似乎提供了高水平的疗效,同时不频繁给药和非常有利的安全性结果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
4.90
自引率
0.00%
发文量
0
审稿时长
>12 weeks
期刊介绍: Seminars in Cutaneous Medicine and Surgery (SCMS) presents well-rounded and authoritative discussions of important clinical areas, especially those undergoing rapid change in the specialty. Each issue, under the direction of the Editors and Guest Editors selected because of their expertise in the subject area, includes the most current information on the diagnosis and management of specific disorders of the skin, as well as the application of the latest scientific findings to patient care.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信